or
Continue with FacebookLooking to list your PhD opportunities? Log in here.
This project is no longer listed on FindAPhD.com and may not be available.
Click here to search FindAPhD.com for PhD studentship opportunities
Dr C Pepper, Dr P Brennan
No more applications being accepted
Funded PhD Project (European/UK Students Only)
About the Project
Following funding from the Leukaemia Research Appeal for Wales, there is an exciting opportunity to pursue a PhD as part of the Cardiff CLL Research Group. Over the past few years, we have developed our expertise in manipulating primary human cells with bioactive peptides. To date we have used these peptides in primary human cells and in cells from patients with chronic lymphocytic leukaemia. We have had success with peptides that target the transcription factor, NF-kappaB which we have shown to be important in CLL. However, NF-kappaB is also known to be important in another B-cell malignancy, multiple myeloma. Myeloma is often a fatal disease with limited treatment options. We propose that applying our technology to myeloma cell lines and samples could provide valuable information for the treatment of this blood cancer. Thus, the aim of this project is to investigate our novel NF-kappaB peptides as therapeutic targets in multiple myeloma. This project will be conducted in collaboration with Dr Arwyn Jones of the Cardiff School of Pharmacy and Pharmaceutical Sciences.
Please submit a CV and covering letter to [Email Address Removed]
Please submit a CV and covering letter to [Email Address Removed]
Funding Notes
at least full UK/EU fees and a stipend matching UK Research Council National Minimum
References
For examples of the kind of work covered by this project, please see the following publications:
Hamilton E, Pearce L, Morgan L, Robinson S, Ware V, Brennan P, Thomas NSB, Yallop D, Devereux S, Fegan C, Buggins AGS, Pepper C (2012) “Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells” Brit J Haem, 158:589-599
Watkins CL, Sayers EJ, Allender C, Barrow D, Fegan C, Brennan P, Jones AT (2011) “Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8.” Mol Ther, 19:2124-2132
Watkins CL, Brennan P, Fegan C, Takayama K, Nakase I, Futaki S, Jones AT (2009) “Cellular uptake, distribution and cytotoxicity of the hydrophobic cell penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide PAD. J Cont Rel 140:237-244
Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennan P, Pepper C (2008) “The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target.” Blood, 111:4681-4689
Hamilton E, Pearce L, Morgan L, Robinson S, Ware V, Brennan P, Thomas NSB, Yallop D, Devereux S, Fegan C, Buggins AGS, Pepper C (2012) “Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells” Brit J Haem, 158:589-599
Watkins CL, Sayers EJ, Allender C, Barrow D, Fegan C, Brennan P, Jones AT (2011) “Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8.” Mol Ther, 19:2124-2132
Watkins CL, Brennan P, Fegan C, Takayama K, Nakase I, Futaki S, Jones AT (2009) “Cellular uptake, distribution and cytotoxicity of the hydrophobic cell penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide PAD. J Cont Rel 140:237-244
Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennan P, Pepper C (2008) “The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target.” Blood, 111:4681-4689
Find a scholarship to fund your dream Masters
Sign in to view and filter all scholarship opportunities
or
Continue with Facebook